INTERNATIONAL PATENT: SAMJIN PHARMACEUTICAL CO., LTD., 삼진제약주식회사 FILES APPLICATION FOR "NOVEL COMPOUND AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME"

GENEVA, Nov. 3 -- SAMJIN PHARMACEUTICAL CO., LTD. (121 Wausan-roMapo-guSeoul 04054), 삼진제약주식회사 (서울특별시마포구와우산로 121) filed a patent application (PCT/IB2025/051508) for "NOVEL COMPOUND AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME" on Feb 13, 2025. With publication no. WO/2025/224512, the details related to the patent application was published on Oct 30, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Invent...